InvestorsHub Logo
Followers 0
Posts 70
Boards Moderated 0
Alias Born 09/06/2007

Re: None

Wednesday, 07/09/2008 1:51:20 PM

Wednesday, July 09, 2008 1:51:20 PM

Post# of 581
LRP has put out a PR on Virulizin which I found encouraging.
Here are some exerpts

Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Wednesday July 9, 8:00 am ET

http://finance.yahoo.com/q?d=t&s=LRP

"TORONTO, July 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced progress made in the Virulizin® development program, including the publication of two research studies on the Virulizin® mode of action and the issuance of a new patent for Virulizin® in Mexico......

Virulizin® has demonstrated significant anticancer activity against a wide range of human cancers in preclinical studies, and has been tested in several clinical trials in solid tumor indications, including a Phase III clinical trial in combination with gemcitabine in locally advanced and metastatic pancreatic cancer. Lorus has reported that the overall survival data in this Phase III study did not reach statistical significance, although exploratory analysis yielded promising results in specific patient populations including in patients with ECOG performance status of 0 or 1."

.....

Virulizin was tried in Mexico with some success against melanoma, but they never finished the effort to get it to market, they were partnered with an Austrailian drug company at the time and the partner could not deal with the Mexican government properly [money talks]. "their culture is incompatible with our standards" is what the Aussie CEO said.

I think LRP can find a way market Viruizin in Europe and Mexico, and it will work quite well and be inexpensive.

Norman





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News